| 尼洛替尼治疗慢性粒细胞白血病的临床观察 |
| |
| 引用本文： | 江慧敏,曾庆曙,倪婧,鲍静,阮敏.尼洛替尼治疗慢性粒细胞白血病的临床观察[J].安徽医科大学学报,2012,47(5):590-592. |
| |
| 作者姓名： | 江慧敏 曾庆曙 倪婧 鲍静 阮敏 |
| |
| 作者单位： | 安徽医科大学第一附属医院血液内科,合肥,230022;安徽医科大学第一附属医院血液内科,合肥,230022;安徽医科大学第一附属医院血液内科,合肥,230022;安徽医科大学第一附属医院血液内科,合肥,230022;安徽医科大学第一附属医院血液内科,合肥,230022 |
| |
| 基金项目： | 2011年度科技厅攻关课题项目 |
| |
| 摘 要： | 观察二代酪氨酸激酶抑制剂(TKI)尼洛替尼对14例伊马替尼耐药或不耐受的慢性粒细胞白血病(CML)患者的疗效及不良反应。14例患者有10例(71.4%)获得血液学完全缓解(CHR),其中2例(20%)缓解后复发。14例患者中2例(14.3%)获得完全遗传学缓解(CCyR),4例(28.6%)获部分遗传学缓解(PCyR),其中1例(16.7%)缓解后3个月复发。提示尼洛替尼对伊马替尼治疗耐药或不耐受的CML患者有较高的血液学及遗传学缓解率。
|
| 关 键 词： | 慢性髓性白血病 尼洛替尼 伊马替尼 |
Clinical effects of nilotinib on chronic myelogenous leukemia |
| |
| Institution: | Jiang Huimin,Zeng Qingshu,Ni Jing,et al(Dept of Hematology,The First Affiliated Hospital of Anhui Medical University,Hefei 230022) |
| |
| Abstract: | To observe the efficacy and adverse reactions of a second-generation tyrosine kinase inhibitor(TKI) nilotinib on 14 chronic myelogenous leukemia(CML) cases who were resistance or intolerance of imatinib therapy.10 cases(71.4%) achieved complete hematologic remission(CHR),2 cases(20%) relapsed after remission.2 cases(14.3%) were complete cytogenetic remission(CCyR),4 cases(28.6%) were partial cytogenetic remission(PCyR),of which 1 case(16.7%) relapsed in 3 months after remission.Nilotinib is a effective drug for the resistance or intolerance of imatinib in patients with CML,which has a higher remission rate of hematology and genetics. |
| |
| Keywords: | chronic myelogenous leukemia nilotinib imatinib |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
